What's New on Dermatology Times: November 29-December 3

LEO Pharma has closed its acquisition of dersimelagon from Tanabe Pharma after the FDA accepted the drug's NDA for filing and granted Priority Review, with a PDUFA date expected by the end of February 2027.

Sol-Gel Technologies has completed patient follow-up in its pivotal phase 3 trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, with top-line results expected in late November 2026.

Two small clinical studies evaluated skincare and dermabrasion for changes in skin quality among individuals taking medical weight loss medications.

Two-year POETYK PsA-2 data showed sustained ACR and minimal disease activity responses with deucravacitinib and no new safety signals.

Faculty from the Cutaneous Oncology Workshop answer practical questions spanning skin cancer prevention, diagnosis, treatment, and follow-up.

Two new Neutrogena facial sunscreens incorporate bemotrizinol, the first new sunscreen active ingredient added to the US OTC monograph in decades.

Longer treatment duration was independently associated with VASI improvement, while publicly insured patients experienced higher topical JAK inhibitor denial rates.

Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.